Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on November 29, 2007

Stroke. 2007
Published online before print November 29, 2007, doi: 10.1161/STROKEAHA.107.493767
A more recent version of this article appeared on January 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
39/1/234    most recent
STROKEAHA.107.493767v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martí-Fàbregas, J.
Right arrow Articles by Martí-Vilalta, J.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martí-Fàbregas, J.
Right arrow Articles by Martí-Vilalta, J.-L.
Related Collections
Right arrow Acute Cerebral Infarction
Right arrow Emergency treatment of Stroke
Right arrow Doppler ultrasound, Transcranial Doppler etc.
Right arrow Thrombolysis
Right arrow Coagulation and fibronolysis

Submitted on May 14, 2007
Accepted on June 7, 2007

Change in Hemostatic Markers After Recombinant Tissue-Type Plasminogen Activator Is Not Associated With the Chance of Recanalization

Joan Martí-Fàbregas PhD*; Montserrat Borrell PhD; Dolores Cocho MD; Sergi Martínez-Ramírez MD; Mercè Martínez-Corral MD; Jordi Fontcuberta PhD; and Josep-Lluis Martí-Vilalta PhD

From the Departments of Neurology (J.M.-F., D.C., S.M.-R., M.M.-C., J.-L.M.-V.) and Hematology (M.B., J.F.), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

* To whom correspondence should be addressed. E-mail: jmarti{at}santpau.es.

Background and Purpose—We evaluated the association between recombinant tissue-type plasminogen activator recanalization and change in hemostatic markers.

Methods—We studied 40 patients. Recanalization was measured with transcranial Doppler. We evaluated the change in markers of coagulation (fibrinogen) and fibrinolysis (thrombin activatable fibrinolysis inhibitor and {alpha}2-antiplasmin) in patients with ischemic stroke treated with recombinant tissue-type plasminogen activator. Samples were obtained before and 90 minutes after recombinant tissue-type plasminogen activator infusion.

Results—The analyses (2-way analysis of variance) showed that the change in the value of each marker did not depend on the vascular patency status.

Conclusion—From a practical point of view, the measurement of these hemostatic markers is probably not useful for predicting recanalization.
Key words: cerebral ischemia • hemostasis • recanalization • reperfusion • thrombolysis






Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.